Elsevier

Surgical Oncology

Volume 3, Issue 2, April 1994, Pages 109-113
Surgical Oncology

Original article
Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma

https://doi.org/10.1016/0960-7404(94)90006-XGet rights and content

Abstract

The epidermal growth factor receptor (EGFR) is structurally similar to the c-erbB-2 oncogene protein. One hundred and nineteen specimens of primary human lung adenocarcinoma were investigated immunohistochemically for the expression of EGFR and the c-erbB-2 protein. Positive staining for EGFR was evident in 55 (46%), and c-erbB-2 protein in 33 (28%) cases. Of the 119 cases, the number staining positively for both the EGFR and c-erbB-2 protein totalled 16 (13%). The incidence of both the expression of EGFR and the c-erbB-2 protein was greater in patients with metastasis1 (M1) than in those with MO (P < 0.01). The 5-year survival rates of patients with EGFR positivity and those with EGFR negativity were 51% and 42% respectively, however, the results did not show statistical significance. On the other hand, the 5-year survival rates of patients with c-erbB-2 positivity and c-erbB-2 negativity were 30% and 52%, respectively, with statistical significance (P < 0.05). Of the cases with EGFR positivity the 5-year survival rates of patients with c-erbB-2 positivity (n = 16) and negativity (n = 39) were 33% and 59%, respectively, with statistical significance (P < 0.05). In contrast, for the EGFR negative cases, the 5-year survival rates of patients who were positive (n = 17) and negative (n = 47) for c-erbB-2 expression were 27% and 46%, respectively, which were not significantly different. Our data thus suggested that erbB oncogenes may play an important role in both the development of cancer and the prognosis of adenocarcinoma of the lung.

References (19)

  • M Tateishi et al.

    Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma

    Eur J Cancer

    (1991)
  • JRC Sainsbury et al.

    Epidermal-growth-factor-receptors and oestrogen receptors in human breast cancer

    Lancet

    (1985)
  • DJ Slamon et al.

    Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

    Science

    (1987)
  • Y Yamada et al.

    Association of elevated expression of the c-erbB-2 protein with spread of breast cancer

    Jpn J Cancer Res

    (1989)
  • H Tsuda et al.

    Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer: its correlation with gene amplification and long-term survival of patients

    Jpn J Cancer Res

    (1990)
  • M Tateishi et al.

    Clinicopathological significance of c-erbB-2 protein expression in human gastric carcinoma

    J Surg Oncol

    (1992)
  • J Downward et al.

    Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences

    Nature

    (1984)
  • L Coussens et al.

    Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

    Science

    (1985)
  • K Suguyama et al.

    Immunohistochemical study in epidermal growth factor and epidermal growth factor receptor in gastric carcinoma

    Cancer

    (1989)
There are more references available in the full text version of this article.

Cited by (85)

  • NSCLC and HER2 between lights and shadows

    2014, Journal of Thoracic Oncology
  • The role of human epidermal growth factor receptor 2 as a prognostic factor in lung cancer: A meta-analysis of published data

    2010, Journal of Thoracic Oncology
    Citation Excerpt :

    The dimerization HER2 with an activated EGFR molecule can activate the downstream signaling pathway.3 HER2 is expressed in the breast,72 ovarian,73 osteosarcoma,74 and lung cancer.5,6,19,21,27,28,30,35–37,40,41,43–48,50,51,53–56,58,59,61–66,69–71,75–77 The most extensive study of HER2 was performed in breast cancer, which links to a potentially poor prognosis.4

  • New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer

    2010, Lung Cancer
    Citation Excerpt :

    In preclinical studies, both EGFR and HER2 have demonstrated the potential to facilitate transformation to a malignant phenotype independently [106] and synergistically [32]. Indeed, high synchronous coexpression of EGFR and HER2 is associated with an unfavorable prognosis in patients with stage I through IIIA NSCLC [107–109]. Such synchronous overexpression may increase the formation of EGFR/HER2 heterodimers, resulting in a more aggressive phenotype.

  • A review of epidermal growth factor receptor/HER2 inhibitors in the treatment of patients with non-small-cell lung cancer

    2010, Clinical Lung Cancer
    Citation Excerpt :

    It may be postulated that synchronous overexpression drives the heterodimerization of EGFR and HER2, which results in increased tumor growth and a decrease in OS and progression-free survival (PFS). Other studies have suggested a relationship between the metastatic potential of NSCLC and EGFR/HER2 coexpression.23 It is noteworthy that increased HER2 gene copy number in EGFR-positive (as measured by immunohistochemistry or fluorescence in situ hybridization) tumors is associated with gefitinib sensitivity and clinical results superior to those seen with tumors that are negative for both receptors.

View all citing articles on Scopus
View full text